Introduction
============

Occupational skin diseases (OSDs) are a significant public health concern both in terms of employee pain and suffering as well as socioeconomic burden. In 2012 for the U.S. alone, the estimated annual direct and indirect costs of OSDs exceeded USD1 billion per annum ([@B59]; [@B21]). Additionally, the cost of dermatological treatments is forecast to reach USD18.5 billion per annum by 2018 ([@B31]). These high socioeconomic costs have provided the impetus for development of efficient *in vitro* screening methods for accurately identifying chemicals with high skin sensitization risk so that their industrial use can be avoided, thereby reducing OSDs. One of the most commonly reported OSDs is contact dermatitis, which accounts for up to 95% of occupation-related skin diseases ([@B58]) in the areas of medicine, beauty products, manufacturing, and the construction industries ([@B41]; [@B57]; [@B87]).

Contact dermatitis is an inflammatory skin reaction resulting from direct contact with foreign substances, mainly affecting exposed skin areas such as the hands, arms, legs, and face ([@B13]). Contact dermatitis can be classified into irritant contact dermatitis and allergic contact dermatitis (ACD). In this review, we address (i) ACD and its associated contact allergens, with particular attention on epoxy resins and their constituents and (ii) *in vitro* methods that may be used for risk assessment of ACD.

Allergic contact dermatitis is a type IV delayed hypersensitivity cutaneous immune reaction that is mediated by T-lymphocytes, and which occurs upon repeated skin exposure to contact allergens ([@B50]). Briefly, ACD develops in two stages, the sensitization phase and the elicitation phase (**Figure [1](#F1){ref-type="fig"}**; [@B92]; [@B52]). During the sensitization phase, contact allergens/haptens initially come into contact with the stratum corneum, the outermost layer of the skin and subsequently gain access to the body system through the viable epidermis. The invasion of haptens triggers the local release of proinflammatory molecules which subsequently induce the binding of haptens to skin proteins ([@B50]). The release of proinflammatory molecules also stimulates the disentanglement and subsequent migration of Langerhans cells (LCs) from the surrounding keratinocytes toward the hapten--protein complex ([@B85]). The hapten--protein complex binds to the major histocompatibility complex (MHC) on LCs and is then transported into the lymph nodes via the afferent lymphatics ([@B92]). During the transitory migration to the lymph nodes, the activated LCs differentiate into mature antigen presenting cells (APCs) resulting in morphological changes such as the loss of endocytic/phagocytic receptors and the upregulation of co-stimulatory molecules and MHC molecules ([@B92]). The hapten--protein complex is presented by the APCs to the naïve hapten-responsive T-cells, followed by selective clonal expansion of effector and memory T-cells. The proliferated population of primed antigen-specific T-cells is then disseminated into the blood circulation resulting in the sensitization of an individual ([@B52]). Elicitation is triggered when the haptens interact with either the same or a different skin site ([@B52]). Upon re-exposure, epidermal cells release a cocktail of proinflammatory cytokines and chemokines which draw the hapten-specific T-cells from the peripheral circulation into the epidermal layer ([@B52]). The infiltrating T-cells produce pro-inflammatory cytokines which in turn trigger the secretion of chemokines by keratinocytes, resulting in increased infiltration of T-cells from blood vessels into the epidermis leading to the development of ACD ([@B10]; [@B92]).

![**Schematic overview of the mechanisms underpinning skin sensitization during sensitization and elicitation phases:** (1) Haptens gain access through the viable epidermis. (2) Binding of haptens and skin proteins. (3) Langerhans cells (LCs) bind to the hapten--protein complex and differentiate into matured dendritic cells (DCs) during migration to the lymph node. (4) LCs present haptenated protein to the naïve T-lymphocytes. (5) Clonal expansion of specific effector and memory T-cells. (6) Proliferated T-lymphocytes disseminate into the blood circulation resulting in sensitization of an individual. (7) Re-exposure of similar haptens to the same individual. (8) Release of proinflammatory cytokines and chemokines by epidermal cells. (9) Infiltration of T-cells from blood vessels into the site of contact. (10) Development of allergic contact dermatitis (ACD).](fphar-06-00094-g001){#F1}

To date, more than 4000 chemical substances are linked to induction of ACD in humans ([@B18]). The 18-year retrospective analysis of ACD patients identified a number of frequently defined contact allergens, some of which have been summarized in **Table [1](#T1){ref-type="table"}** ([@B18]). These chemicals have been compiled in several human patch tests series including the North American Series, the European Baseline Series, the International Standard Series and the Thin-layer Rapid Use Epicutaneous Tests (TRUE). In brief, these series identify chemical substances commonly implicated in the population of a given geographical area, to cause ACD ([@B88]).

###### 

Common allergens and sources of exposure.

  Allergens                  Source
  -------------------------- ----------------------------
  Epoxy resin system (ERS)   Adhesives, paints
  Formaldehyde               Pesticides, home cleansers
  Fragrance mix              Toiletries, cosmetics
  Neomycin sulfate           Creams, deodorants
  Nickel sulfate             Costume jewelry, tools
                             

Epoxy resin-induced ACD was first reported in the 1950s, a time when there was extensive development of epoxy resin systems (ERSs) in industry ([@B16]). In general, an ERS is comprised of an epoxy resin, hardener, reactive diluent, or other additives such as solvents, modifiers and fillers which together control the chemical and physical properties of the ERS ([@B36]; [@B71]).

Epoxy resin system components are the third most common allergen types for occupational ACD after chromates and rubber allergens, with ERS the primary source of ACD in the plastics manufacturing industry ([@B36]). The prevalence of ERS-induced ACD by country is summarized in **Table [2](#T2){ref-type="table"}**.

###### 

Reported prevalence of occupational allergic contact dermatitis (ACD) due to epoxy resin systems (ERS).

  Study period   Country         Study population (number of individuals)   Prevalence of ERS-induced ACD (%)   Reference
  -------------- --------------- ------------------------------------------ ----------------------------------- -----------
  1993--2002     Australia       1354                                       3.0                                 [@B17]
  1996--2006     North America   2540                                       0.9                                 [@B5]
  1997--2001     Norway          2336                                       1.0                                 [@B80]
  1999--2008     Portugal        2440                                       0.6                                 [@B19]
  2001--2010     Denmark         219                                        8.2                                 [@B65]
  2001--2006     China           1354                                       8.5                                 [@B22]
  2005--2009     Denmark         20 808                                     1.3                                 [@B8]
  2006--2008     Lithuania       816                                        1.5                                 [@B12]

It was estimated that for individuals with ERS-associated ACD, ∼60--80% were sensitized to diglycidyl ether bisphenol A (DGEBA), an ERS that is widely used in industry ([@B15]). This high prevalence resulted in the inclusion of DGEBA in the human patch test series since the 1960s ([@B36]). Other epoxy resins including diglycidyl ether bisphenol F (DGEBF) and tetraglycidylmethylenedianiline, are also associated with induction of ACD ([@B36]; [@B71]).

Apart from epoxy resins, epoxy hardeners, predominantly polyamine compounds such as triethylenetetramine (TETA) and diethylenetriamine (DETA), as well as reactive epoxy diluents (e.g., phenyl glycidyl ether and *p*-tert-butylphenyl glycidyl; [@B35]), also cause ACD. A retrospective analysis of the records of 182 patients with ACD induced by epoxy resins over a 22-year period showed that 23.6% had developed an allergic response to epoxy hardeners ([@B46]). In a prospective study involving 92 individuals with suspected and/or prior exposure to ERS, patch tests showed that they were responsive to the epoxy diluents, 1,6-hexanediol diglycidyl ether (19.5%), and 1,4-butanediol diglycidyl ether (18.5%; [@B35]), highlighting cross-reactivity between epoxy compounds for induction of ACD in humans.

Although the high propensity of ERS to induce ACD is known, they are nevertheless used widely in commercial thermosetting products due to their strong adhesive bonding properties between different surfaces while exhibiting excellent resistance in harsh chemical and environmental conditions ([@B18]). Worldwide demand for epoxy resins is forecast to reach ∼3 million tons by the end of 2017, with an estimated value of USD9.2 billion per annum ([@B39]; [@B60]). The high global demand for epoxy resins is due to their ever increasing utility in a wide range of industrial applications including automotive coatings, electronic coatings, construction and adhesive products ([@B26]; [@B39]). At present, research on assessment of the generalizability of *in vitro* tests developed for identifying the skin sensitizing potential of small molecules used in the toiletries and cosmetics industries, to that of epoxy resins and their components, is limited. Hence, this knowledge gap needs to be addressed. Herein, we review recent developments in non-animal tests for screening industrial chemicals for skin sensitization potential, with particular attention to the applicability of these tests to the epoxy resin chemical class.

Contact Allergens Screening Approaches
======================================

Development of the first animal models more than 80 years ago, to substitute for human skin patch testing of chemical compounds as potential contact allergens, was a landmark in terms of minimizing if not altogether avoiding the need for human testing ([@B55]). About 40 years later, animal models were introduced for assessing the sensitizing capacity of ERS ([@B91]; [@B90]; [@B34]; [@B76]). At present, the murine local lymph node assay (LLNA) is the 'gold standard' for assessing the skin sensitization potential of contact allergens. However, the use of animals for this type of testing has provoked much ethical debate ([@B20]; [@B9]) and provided the impetus over the past decade for the development of *in vitro* methods to replace, reduce, and refine (3Rs) this type of animal testing ([@B32]). Although several of these non-animal testing methods are at the pre-validation stage, they have been used primarily to assess the skin sensitization potential of small molecules (molecular weights \<500 Da) such as those used in the manufacture of cosmetic and toiletry products ([@B48]). However, their applicability for assessment of the skin sensitization potential of ERS is largely unexplored. Hence this knowledge gap needs to be addressed to enable the best method or combination of methods to be identified for the reliable assessment of the skin sensitization potential of epoxy resin compounds. In the following sections we review the current non-animal testing approaches that have been developed based upon key mechanistic events in the process of skin sensitization and address the limitations of these methods for assessing the skin sensitization potential of ERS.

*In Chemico* Assays: Peptide--Chemical Interactions
---------------------------------------------------

Epoxy resins and/or epoxy resin composite materials, in common with other classes of haptens, react with skin proteins. The hapten--protein complex is then internalized and processed by LCs ([@B4]). Protein modification, in a process known as haptenation, is a key step in the initiation of skin sensitization ([@B23]). Majority of contact allergens are electrophilic in nature, consisting of Michael acceptors, S~N~Ar and S~N~2 electrophiles, Schiff base formers, or acylating agents, which underpin their ability to react with the nucleophilic amino acid residues of skin proteins ([@B23]; [@B54]). For epoxy resins, the electrophilic epoxide groups react with the nucleophilic moieties of skin proteins via S~N~1 or S~N~2 type nucleophilic reactions ([@B72]).

This haptenation process is mimicked *in vitro* by the direct peptide reactivity assay (DPRA; **Figure [2A](#F2){ref-type="fig"}**) which assesses depletion of small proteins (peptides) secondary to their interaction with potential haptens ([@B38]). Briefly, in this model, synthetic peptides containing nucleophilic residues including cysteine or lysine are incubated with test chemicals at a pre-determined ratio for 24 h to allow the binding of the active side chain of the peptide to the hapten. Based upon the irreversible covalent bond formation that occurs between haptens and amino acid residues in proteins, the DPRA quantifies the amount of unbound (remaining) peptide in the reaction mixture using high performance liquid chromatography (HPLC). Subsequently, the quantification of the bound (depleted) peptides is determined as a measure of reactivity of the test chemical ([@B37]).

![**Schematic diagram summarizing the steps involved in the conduct of *in vitro* assays currently available for assessment of skin sensitization potential. (A)** Direct peptide reactivity assay (DPRA), **(B)** human cell line activation test (h-CLAT), **(C)** myeloid U937 skin sensitization test (MUSST), **(D)** KeratinoSens^TM^, **(E)** loose-fit coculture-based sensitization assay (LCSA), **(F)** genomic allergen rapid detection (GARD), and **(G)** human T-cell priming assay (hTCPA).](fphar-06-00094-g002){#F2}

At present, the DPRA has been validated by the European Centre for the Validation of Alternative Methods (ECVAMs) for the assessment of contact allergens as a replacement for the *in vivo* LLNA ([@B93]). A test guideline has been promulgated by the Organization for Economic Co-operation and Development (OECD) highlighting the generalizability of peptide reactivity with small molecules ([@B75]). However, the suitability of the DPRA test system for chemicals such as epoxy resins that contain an epoxide group remains to be assessed.

### DPRA: Chemicals Tested to Date

Use of the DPRA to assess the ability of 82 compounds that are mainly used as ingredients in cosmetic and toiletry products, to deplete cysteine-, lysine-, and glutathione-based peptides, indicated a significant correlation between peptide depletion and their sensitizer potency as previously established from *in vivo* LLNA data ([@B38]).

Steps undertaken to improve the accuracy of the DPRA for identification of potential skin sensitizing chemicals have included incorporation of oxidizing agents such as horseradish peroxidase and hydrogen peroxide (HRP/P) as well as cytochrome P450 enzymes to metabolically activate unreactive haptens into their more reactive hapten form, a process that may take place in human skin *in vivo* ([@B14]; [@B93]). By incorporating HRP/P into the DPRA, 83% of 70 chemicals with known sensitizing potential were identified accurately as compared with the standard DPRA reported previously (89%; [@B93]). This apparently reduced accuracy of the HRP/P-added DPRA analysis is misleading, however, as the initial chemical set used to evaluate the previous DPRA prediction model did not include pre-/pro-haptens ([@B38]).

More recent refinements aimed at increasing the robustness of the DPRA to identify skin sensitizing chemicals include using pH conditions that more closely mimic human skin pH and measurement of concomitant chemical-specific mass changes indicative of peptide adduct formation ([@B28]). In other work, the rate constant for reactivity of various test chemicals with the DPRA peptide was determined to assess whether quantitative kinetic reactivity data generated by measuring cysteine depletion at multiple test chemical concentrations and at various incubation times, were correlated with their potency as sensitizers ([@B79]; [@B68]). However, drawbacks of this approach are that chemical reactivity varies markedly between various functional groups and the reaction rate of test chemicals with the DPRA peptide may not be linearly related to their *in vivo* sensitization potency ([@B79]).

### DPRA: Application to ERS

While cysteine and lysine are the most widely utilized peptides for the *in vitro* DPRA, other modified peptides have been investigated. More recently, the utility of the DPRA for classifying the sensitizing capacity of several epoxies including novel analogs of DGEBF and phenyl glycidyl ether (PGE), has been examined using a synthetic peptide, viz PHCKRM (Pro-His-Cys-Lys-Arg-Met). The extent of peptide (PHCKRM) depletion by six novel epoxy analogs and the parent epoxide, PGE, was correlated with the sensitizing potency of these epoxies determined using *in vivo* LLNA assessment ([@B70]). The strong sensitizer, PGE produced 88% peptide depletion whereas the weak epoxide sensitizers, butyl glycidyl ether, and butenyl glycidyl ether produced 46 and 54% peptide depletion, respectively ([@B70]). In a DPRA evaluation of DGEBF (containing two epoxide groups) and two variants (Variant A and Variant B) using the same synthetic peptide (PHCKRM), the thiol (cysteine) binding of DGEBF and its variants appeared to be affected by the terminal epoxide groups ([@B73]). Variant A (DGEBF without terminal epoxide groups) did not react with free thiols whereas variant B (DGEBF with one terminal epoxide group) did react with thiol groups albeit to a slightly lesser extent than the diepoxide DGEBF. Interestingly, the reaction rate for DGEBF that contains two terminal epoxide groups was slightly faster than that of variant B. These findings are aligned with the sensitizing capacity of DGEBF and its variants determined using the LLNA and the KeratinoSens^TM^ assay ([@B73]).

To date, reports on the applicability of the incorporation of enzymes into the DPRA, as a means of bioactivation for assessing the skin sensitization potential of epoxy resins, are lacking. It is known that the enzyme, epoxide hydrolase, catalyzes the hydrolysis of epoxides to their respective dihydrodiol metabolites which react readily with skin proteins. Conversely, the enzyme, glutathione-*S*-transferase catalyzes the detoxification of epoxides by formation of glutathione conjugates ([@B72]). Hence, future investigation involving incorporation of epoxide hydrolase and/or glutathione-*S*-transferase into the DPRA for analysis of epoxy resin compounds is warranted, to more closely mimic possible bioactivation and deactivation processes within human skin that produce reactive electrophilic intermediates and detoxified species, respectively.

Issues relating to the poor aqueous solubility of industrial compounds that have high octanol/water partition coefficients, present another obstacle for use of DPRA to assess compounds such as epoxy resins. Although various solvents including dimethylsulfoxide (DMSO), methanol and acetonitrile have been used to dissolve lipophilic compounds, only small volumes of these solutions can be used due to their limited miscibility with an aqueous solution of the peptide to be depleted. To that extent, microemulsion systems have potential to improve miscibility between an organic solution of a lipophilic test compound and that of an aqueous peptide solution; preliminary data suggest that this approach is worthy of further investigation ([@B63]).

Unacceptable modulation of the test systems by organic solvents limits the range of solvents that can be used for dissolution of epoxy resins. For example, organic solvents routinely used in laboratories inhibit cytochrome P450-mediated metabolic reactions, and may potentially fail to activate the enzyme-dependent sensitizing chemicals in the test system ([@B56]; [@B93]). DMSO is unsuitable for use in the DPRA as its high reactivity means that it may react with assay peptides resulting in false positive results. The use of DMSO in the DPRA would require an additional costly step of purging the reaction system with an inert gas such as argon, to prevent oxidation of DMSO ([@B70]).

*In Vitro* Assays: Cell-Based Models
------------------------------------

Human LCs and dendritic cells (DCs) play key roles in skin sensitization ([@B24]). Hence, there has been considerable research attention on development of *in vitro* systems that mimic the roles of LCs and DCs in skin sensitization. Initial *in vitro* assays using LCs/DCs were limited due to the scarcity of available LCs and inter-donor variability of DCs ([@B99]). These factors were compounded by between-laboratory variability in cell isolation and cell culture techniques, which led to assay reproducibility problems ([@B99]). The inter-donor variability was circumvented by the use of human myeloid cell lines, such as KG-1, THP-1, MUTZ-3, and U937 that have the ability to differentiate into cells with DC-like characteristics ([@B42]; [@B53]; [@B99]). Several *in vitro* model systems using human cell lines to assess the skin sensitizing potential of contact allergens have been developed. These include the human cell line activation assay (h-CLAT), myeloid U937 skin sensitization test (MUSST), the KeratinoSens^TM^ test (**Figures [2B--D](#F2){ref-type="fig"}**) and the LuSens which were under ECVAM evaluation ([@B1]; [@B7]; [@B82]; [@B77]; [@B30]; [@B11]). These methods have been reviewed extensively by others ([@B62]; [@B96]), and hence will not be covered in this review.

### Loose-Fit Coculture-Based Sensitization Assay (LCSA)

An allergen-sensitive *in vitro* method that combines two layers of cells, termed the loose-fit coculture-based sensitization assay (LCSA), was developed using human primary keratinocytes from healthy donors, and mobile DC-like cells viz peripheral blood mononuclear cells (PBMCs; **Figure [2E](#F2){ref-type="fig"}**; [@B84]). As keratinocytes are proposed to have a role in haptenation via maturation of DCs, this assay has the advantage of being able to detect prohaptens such as isoeugenol ([@B84]), that are not detected by many *in vitro* model systems. In short, inclusion of keratinocytes in this two-tiered cell-based system facilitated metabolic activation of prohaptens into sensitizing agents akin to that which occurs in the skin *in vivo* ([@B98]).

Similarly to MUSST and h-CLAT (as depicted in **Figures [2B,C](#F2){ref-type="fig"}**), LCSA quantifies the increase in expression of the cell surface marker, CD86 ([@B83]). Additionally, LCSA accuracy and sensitivity for assessing metal allergens such as nickel and cobalt, was improved by measuring accumulation of the proinflammatory cytokine, interleukin-6 (IL-6) and the chemokine macrophage inflammatory protein 1-β (MIP-1β; [@B84]). In a comparative evaluation of the *in vitro* LCSA relative to the *in vivo* LLNA for assessing the skin sensitizing potential of a group of textile disperse dyes, both methods identified 87.5% of these dyes as having skin sensitizing potential. Hence, the LCSA is a promising *in vitro* method for identifying agents with skin sensitizing potential for use in combination with other non-animal testing methods ([@B86]). However, the current challenges in using the LCSA include the necessity to obtain keratinocytes and PBMCs from healthy human donors which makes the method susceptible to inter-donor variability. Additionally, the complexity and time required for seeding keratinocytes and PBMCs in this co-culture assay makes it low throughput and so future innovation is required to adapt the LCSA to high throughput format.

### Genomic Allergen Rapid Detection (GARD)

Apart from quantification of changes in cell surface expression of molecules of interest, genomic methods may offer an alternative or complementary *in vitro* testing paradigm. For example, genomic allergen rapid detection (GARD) employs the myeloid cell line, MUTZ-3 that resembles skin DCs with respect to transcriptional profiles and the ability to activate specific T-cell populations (**Figure [2F](#F2){ref-type="fig"}**; [@B44]). GARD uses a complete genome expression array approach to measure expression levels of 200 transcripts involved in the activation of various signaling pathways involved in skin sensitization.

Unlike the KeratinoSens^TM^, MUSST and h-CLAT *in vitro* methods that use specific markers for classifying sensitizers, GARD utilizes 'biomarker signatures' for identifying skin sensitizers, thereby potentially increasing the predictive ability of the method. An added advantage of GARD is that it can distinguish respiratory and skin allergens by their unique biomarker signatures ([@B44]). Encouragingly, use of GARD to assess 38 chemicals with known skin sensitization potential in a preliminary study, showed that the accuracy, sensitivity, and specificity of the method was high at 99% ([@B45]).

Recently, [@B3] stressed that chemical reactivity properties were key factors for consideration when developing *in vitro* screening models of chemical sensitizers. Sensitizing chemicals were divided into groups based upon their mechanistic reactivity and assessed against various cell-signaling pathways using the GARD assay. Interestingly, different chemical reactivity groups induced differential changes in various cell signaling pathways, particularly those involved in cell cycling and metabolism. Potency in modulating these pathways appeared to be correlated with skin sensitization potential ([@B3]). However, care is required to avoid over-interpretation of these associations with respect to potential sensitizer classification. More work is clearly required using larger numbers of chemicals with a broad range of functional groups of varying reactivity, as well as a range of concentrations and reaction times. Nevertheless, the GARD assay can provide invaluable information on the various cell signaling pathways underpinning the sensitization process which is invaluable in informing further development of *in vitro* sensitization test methods. Future research is warranted to assess the extent to which the epoxide group in ERS will modulate cell-signaling responses based upon their reactivity domain and/or their sensitizing potency.

### T-cell Activation Model

During skin sensitization, specific effector and memory T-cells are activated by DCs triggered by sensitizing agents. While activation and proliferation of T-cells reflect the ultimate step in inducing sensitization, there are very few assays that address this aspect of the sensitization process. At present, only the *in vivo* LLNA is used widely to evaluate the activation and expansion of T-cells. More recently, an *in vitro* assay known as the human T-cell priming assay (hTCPA) was developed to assess T-cell responses initiated by contact allergens (**Figure [2G](#F2){ref-type="fig"}**; [@B27]; [@B78]). The hTCPA uses naïve T-cells isolated from PBMCs of healthy donors that are depleted in CD25^+^ and CD45RO^+,^ a T-cell population responsible for regulating hapten-specific interferon-γ (IFN-γ)-producing T-cells in lymph nodes ([@B96]). The modified T-cells are co-cultured with hapten-treated monocyte-derived DCs at two stages, priming and re-stimulation. After re-stimulation, the increase in T-cell production and the cytokines, IFN-γ and TNF-α (tumor necrosis factor-α), are quantified using an enzyme-linked immunosorbent assay (ELISA) and an intracellular cytokine assay ([@B78]; [@B96]).

The hTCPA has been used successfully to assess the skin sensitizing potential of the strong sensitizers, 2,4-dinitrochlorobenzene (DNCB), 2,4-dinitrobenzenesulfonic acid (DNBS) 2,4,6-trinitrobezene sulfonic acid (TNBS), and moderate/weak sensitizers, fluorescein isothiocyanate (FITC), and α-hexyl cinnamaldehyde (HCA) as well as the non-sensitizers, methyl salicylate, DMSO, and sodium lauryl sulfate (SLS; [@B97]). Hence, the hTCPA has potential as an *in vitro* method for assessing the sensitizing potential of contact allergens. However, similar to the LSCA, this method is time-consuming and fraught with difficulty in assay reproducibility due to the scarcity of T-cell donors and inter-donor variability. More work is warranted to assess the applicability and generalizability of this cell-based model system using a larger number and a wider range of chemical compound classes. For example, the hydrophobic compound, DNCB that reduced DCs uptake did not stimulate T-cell proliferation ([@B27]). While the use of nanoparticle encapsulation of lipophilic compounds significantly increased the ability of DNCB to stimulate T-cell proliferation and thus increase the assay sensitivity ([@B96]), inclusion of this additional step adds another level of complexity and increases the cost of the assay.

### Cell-Based Models and ERS

Despite significant progress in the development and optimization of non-animal testing assays, a major limitation in their use for accurately identifying the skin sensitizing capacity of test compounds, is poor water solubility, particularly for aqueous cell-based assays ([@B61]). To date, few ERS compounds have been assessed using cell-based *in vitro* model systems. While the KeratinoSens^TM^ assay has been used successfully to classify the skin sensitizing potential of DGEBA, DGEBF, and PGE ([@B25]; [@B73]; [@B69]) to match the LLNA results, the generalizability of other *in vitro* cell-based methods reviewed herein is a knowledge gap and remains to be determined.

Maintaining a suitable balance between the final solvent composition, test compound solubility and deleterious solvent-related effects within the assay, is pivotal for generating meaningful data on skin sensitization potential. In general, the solvent-related issues associated with *in vitro* assays relate to toxicity and/or solvent-mediated modulation of the assay response, thereby confounding assay readouts resulting in inaccurate assessment of skin sensitization potential. High solvent concentrations in cell-based assays adversely affect cellular integrity, resulting in cell death ([@B89]; [@B33]). Concentration-related toxic effects of the solvent need be evaluated to identify the maximum 'no effect' levels for each *in vitro* assay. The balance between acceptable solvent percentage in the aqueous cell-based test system whilst maintaining solubility of high molecular weight and low solubility test compounds, particularly industrial epoxy resins is yet to be adequately addressed. This issue is arguably the most significant obstacle to be overcome in adapting current *in vitro* skin sensitization assays to assessment of epoxy resin hazard risk.

Skin Models
===========

While selection of solvents compatible with *in chemico* assays may improve the ability of the DPRA to identify epoxy resins that have skin sensitizing properties, it is more difficult to attain a suitable balance between epoxy resin solubility and cell viability in aqueous culture-based assays. Moreover, future investigation is required regarding the fact that most test compounds are applied in solution to *in vitro* assays which may not necessarily be reflective of the situation in humans where there may be topical application of the compound in the solid state to the skin. To address this issue, the reconstructed human epidermis (RHE) has considerable potential. The RHE comprises an acellular dermal matrix mimicking the human skin epidermis layer. It has been used together with cytokines and growth factors to better represent the human skin micro-environment ([@B40]). Preliminary data using the RHE system showed that it was responsive to known sensitizers ([@B94]).

More recently, EpiSensA, an *in vitro* skin sensitization assay that utilizes a commercially available RHE has become available ([@B81]). In brief, using this skin model system, skin sensitizing potential of test compounds is assessed based upon changes in the expression of genes related to the cellular stress response. Preliminary data from 16 test compounds were promising ([@B81]). Despite considerable progress, the challenge remains for a more complete human skin model system to become available that has a high degree of accuracy for correctly identifying and classifying the skin sensitization potential of novel compounds. This challenge is multi-factorial encompassing inter-individual differences at both the cellular and molecular levels such as genotypic variation, differences in epidermal thickness and metabolic activity of the skin, as well as inter-individual differences in rates of skin cell differentiation ([@B40]). Nevertheless, EpiSensA has promise for improving *in vitro* assessment of the skin sensitizing properties of compounds with poor aqueous solubility such as epoxy resins.

Challenges in Assessing Epoxy Resin Compounds Using non-Animal Testing Systems
==============================================================================

Apart from use of RHE model systems, the accuracy of *in vitro* methods for skin sensitization assessment of industrial chemicals may be improved by including multiple assay readouts using an 'assay panel' approach ([@B67]; [@B43]; [@B11]). However, questions on the generalizability of these *in vitro* methods to accurately identify chemicals containing very different functional groups, is as yet unclear. In particular, most *in vitro* methods were developed and evaluated using small molecule chemicals that are widely utilized in the manufacture of cosmetic and toiletry products. This is a significant limitation as it has now been shown that different functional groups with varying chemical reactivity produce differential engagement of cell signaling pathways ([@B3]).

For example, a dataset of 145 chemical compounds assessed using the KeratinoSens^TM^ and MUSST assays, those that were preferentially lysine-reactive resulted in false negatives ([@B69]). These findings mirror work by others ([@B64]) whereby chemicals with high reactivity toward cysteine, and not lysine, activated the nuclear factor erythroid-derived 2-related factor 2 (Nrf2)-ARE pathway in THP-1 cells, a well-known toxicity pathway activated by skin sensitizers ([@B66]) that underpins the design principles of both the KeratinoSens^TM^ and LuSens tests. ERS compounds such as DGEBA, DGEBF, and PGE react selectively with thiol groups (cysteine; [@B73]; [@B69]). Hence, the KeratinoSens^TM^ and LuSens assays that are based on the aforementioned pathway are worthy of future investigation for their applicability and reliability to assessment of the skin sensitizing potential of epoxy resins.

However, it is important to bear in mind that a single stand-alone method based upon a single mechanistic pathway to assess novel derivatives of ERS compounds is fraught as the novel derivatives may produce skin sensitization by a different mechanistic pathway. To address this issue, ECVAM recommendations are that the KeratinoSens^TM^ be used as part of an integrated assessment approach that may also include the DPRA ([@B29]). Hence, future research is required to assess the applicability of current *in vitro* methods to assess the skin sensitizing potential of a broader range of chemical compounds as a means to identify the most appropriate *in vitro* assays and assay readout ranges, for establishing benchmarks to use for classifying the skin sensitization potency of novel compound classes.

Another consideration to this discussion is the inherent accuracy of the LLNA itself with respect to existing human data. The LLNA is widely utilized as the benchmark for evaluating the predictive accuracy of non-animal methods. However, when compared against the human maximization and patch test, the accuracy of the LLNA was 72% ([@B6]). More recently, a retrospective comparison of a moderately large dataset (\>100) of test compounds revealed an 82% predictive accuracy for LLNA when compared with established human data ([@B95]). In other work, use of an integrated testing strategy-based on data from '2 out of 3 *in vitro* prediction models' resulted in a higher overall accuracy (≥90%) when compared with human data, as opposed to ≤83% using the LLNA dataset ([@B11]; [@B95]). Factors potentially contributing to the discordance between human and LLNA data include the difference in skin penetration rates between the mouse and human, as well as the application method of the test compounds on the skin ([@B6]; [@B25]). The volatility and cytotoxicity of compounds such as the components of ERS, could affect potency outcomes given the open nature of substance application to the mouse ear in the LLNA in contrast with the occluded dressing used in human patch tests ([@B25]). Hence, where possible, it is important to compare data produced by various *in vitro* skin sensitization tests with human data where available rather than relying solely on comparisons with LLNA data.

Integrating Non-Animal Assay Readouts: Classifying Potential Skin Sensitizers
=============================================================================

The OECD has proposed that the hazard classifying system for chemicals should consider the potential severity of allergic manifestations from human and animal-based epidemiological data \[[@B74]\]. A strong sensitizer is defined as a compound that has a high occurrence of sensitization within an exposed population whereas low to moderate sensitizers produce a low or moderate frequency or severity of sensitization \[[@B74]\]. At present, this chemical classification system is based solely on the 'gold standard' LLNA which assesses the potency of skin sensitizers based on the extent to which they induce T-cell proliferation in the auricular lymph nodes of mice ([@B51]). Current and future research aimed at gaining a deeper understanding of the various cellular and immunological mechanisms and their interplay that contribute to the extent of sensitization evoked, is essential. Such new knowledge will be invaluable for informing future research aimed at optimization of *in vitro* methods for hazard identification of industrial chemicals, particularly ERS, as well as enable quantitative risk assessments to be performed ([@B52]).

The available non-animal testing methods for assessing the various stages of ACD are summarized in **Figure [3](#F3){ref-type="fig"}**. This schematic diagram clearly shows that single testing methods are unable to evaluate potential cross-talk between the various phases of the skin sensitization process. Thus, a single *in vitro* test representative of a single event in the human skin response to contact allergens cannot adequately capture the complexity of the human response to a contact allergen, thereby potentially leading to generation of false negative results ([@B2]). Thus, a panel of complementary non-animal tests that together mimic the complexity inherent in *in vivo* test methods (e.g., LLNA, human patch test), has considerable potential utility as a screening tool for more accurately classifying novel compounds as extreme, strong, moderate or weak sensitizers.

![**Schematic overview of mechanisms underpinning non-animal methods for assessing the sensitizing potential of chemical compounds.** (1) Penetration of haptens through the viable epidermis: Quantitative Structure--Activity Relationship (QSAR). (2) Activation of keratinocytes in the epidermal layer by haptens: KeratinoSens^TM^, LuSens. (3) Secretion of danger signals from the epidermal compartment due to invasion of haptens: ROS production, genomic fingerprints, and proteomics biomarkers. (4) Formation of the hapten--protein complex: DPRA, peroxidase peptide reactivity assay (PPRA) and QSAR, Allergen-peptide/protein interaction assay (APIA). (5) Maturation of DCs when migrating from epidermal compartment to auricular lymph nodes via afferent lymphatics: h-CLAT, MUSST, LCSA. (6) T-cell proliferation in auricular lymph nodes: hTCPA.](fphar-06-00094-g003){#F3}

An integrated hazard classification scheme involving assessment of multiple steps in the skin sensitization process, including bioavailability, structural alerts, formation of hapten--protein conjugates, DC maturation, and T-cell proliferation, has been proposed ([@B49]; [@B47]). Using this approach, greater weight is given to *in vitro* tests that produce quantitative data. An index of sensitizing potency is calculated based upon the product of values obtained from each test representing a key step in the skin sensitization process, for comparison of skin sensitization potency with the corresponding mouse LLNA data ([@B49]; [@B47]). Various non-animal test combinations proposed for identifying potential skin sensitizers are summarized in **Table [3](#T3){ref-type="table"}**.

###### 

*In vitro* methods used in combination for classifying and predicting skin sensitization potential of novel chemical compounds.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Combination methods                                                                      Description                                                                                                        Accuracy                     Reference
  ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ---------------------------- -----------
  \(a\) Peptide reactivity\                                                                • Scores of 0--4 for each individual test\                                                                         88% (based on LLNA data)\    [@B67]
  (b) Cell-based ARE^†^ assay\                                                             • A binary system is applied for *in silico* test results                                                          (116 test substances)        
  (c) TIMES-SS^‡^ computer modelling\                                                                                                                                                                                                      
  (d) Calculated octanol-water partition coefficient                                                                                                                                                                                       

                                                                                                                                                                                                                                           

  \(a\) DPRA\                                                                              • A sensitizer if DPRA and LuSens yield negative results and MUSST is positive\                                    94% (based on human data)\   [@B11]
  (b) LuSens (similar principle with KeratinoSens^TM^ assay) or KerotinoSens^TM^ assays\   • If contradictory results between DPRA and LuSens, or h-CLAT, then weight of evidence approach is used            83% (based on LLNA data)\    
  (c) h-CLAT or MUSST                                                                                                                                                                                         (54 test substances)         

                                                                                                                                                                                                                                           

  Bayesian network Integrated Testing Strategy\                                            • Adaptive testing strategy where the choice and sequence of tests performed are based on available information\   --                           [@B43]
  (a) TIMES^§^\                                                                            • Reduces uncertainty of the sensitizing capacity of a test substance before proceeding to the experiment.                                      
  (b) DPRA\                                                                                                                                                                                                                                
  (c) ARE luciferase activity\                                                                                                                                                                                                             
  (d) MUSST                                                                                                                                                                                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

†

ARE, antioxidant

response element.

‡

TIMES-SS, tissue metabolism simulator for skin sensitization.

§

TIMES, tissue metabolism simulator.

Conclusion
==========

A strategy encompassing the integration of readouts from multiple *in vitro* tests as a means to improve the accuracy for identification of novel compounds that are contact allergens has merit. However, implementation of such a strategy requires extensive validation and assessment of its generalizability for multiple chemical classes before gaining widespread acceptance. Additionally, use of an integrated panel of *in vitro* methods to screen large numbers of industrial chemicals is likely to be unattractive from a cost and time perspective and so development of a hierarchy of individual high throughput *in vitro* tests is needed.

At present, single *in vitro* assays in high throughput format enable large numbers of compounds to be screened in a short time frame. However, the choice of *in vitro* method for screening purposes, either as part of an integrated or hierarchical strategy, should be informed by knowledge of the chemical class/domain. In conclusion, the choice of *in vitro* methods for inclusion in a panel for assessing skin sensitization potential will be the best balance between predictive power of the selected tests relative to the time and cost of generating the data and its value to the organization that requires the data.
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